Trial Profile
Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2015
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Pamidronic acid (Primary)
- Indications Spondylarthritis
- Focus Therapeutic Use
- 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Nov 2012 New trial record